Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 8,233-8,244 of 23,847
Drug study icon
CompletedNCT00566449

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

This study exists to compare options and see whether the medication JNJ-31001074 offers something meaningfully different. Researchers are trying to understand whether the medication JNJ-31001074 can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Irvine
ADHDDrugA study involving a medication or substance.From 18 Years to 64 Years
Countries
United States
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
ADHD
Drug study icon
CompletedNCT02432703

Safety study of JNJ-42165279 in anxiety

This study is completed in the United States, in Australia, and in Canada. It is testing JNJ-42165279 for anxiety.

Multiple locations, including La Jolla
AnxietyDrugFrom 18 Years to 64 Years
Countries
United States, Australia, Canada
Sponsor
Janssen Research & Development, LLC
Condition
Anxiety
Drug study icon
WithdrawnNCT01685151

Ramelteon Tablets for Bipolarity

This study was withdrawn. It is testing ramelteon Tablets for Bipolarity.

Location not clearly listed
BipolarityDrugFrom 18 Years to 75 Years
Countries
Sponsor
Takeda
Condition
Bipolarity
Drug study icon
CompletedNCT00796081

Safety study of ER OROS Paliperidone in schizophrenia

This study is completed. It is testing ER OROS Paliperidone for schizophrenia.

Location not clearly listed
SchizophreniaDrugFrom 10 Years to 17 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.